RTTNews | Sep 2, 2021 07:31AM EDT

07:31 Thursday, September 2, 2021 (RTTNews.com) - Chemomab Therapeutics Ltd. (CMMB), an Israeli clinical-stage biotech company, announced Thursday that it has appointed Dale Pfost as Chief Executive Officer. Pfost is expected to join the Board of Directors and subsequently become the company's Chairman in 2022.

Adi Mor, company co-founder and current CEO, will continue in her role as Chief Scientific Officer and remain as a member of the Board of Directors.

Pfost's appointment as CEO and member of the Board will become effective upon the approval of Chemomab shareholders, as is required for public companies based in Israel. A shareholder vote is expected in the fourth quarter of 2021.

His expected appointment as Chairman in 2022 will also require shareholder approval.

Pfost brings more than 30 years of diverse experience as a life science senior executive, entrepreneur and venture investor.

Pfost was Chairman and CEO of innovative drug discovery firm Lodo Therapeutics until it was acquired in May of this year. Previously, he was the U.S.-based General Partner at London-based venture capital firm Advent Life Sciences.

He has served as CEO of six biotechnology companies, three of which became publicly traded with valuations exceeding two billion dollars.

Read the original article on RTTNews ( https://www.rttnews.com/3222869/chemomab-therapeutics-names-dale-pfost-ceo-chairman-designate-quick-facts.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved